| Diabetes Mellitus, Non-Insulin-Dependent
Atorvaliq vs Xultophy
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Atorvaliq vs Xultophy 100/3.6 with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXultophy 100/3.6 has a higher rate of injection site reactions vs Atorvaliq based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xultophy 100/3.6 but not Atorvaliq, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Atorvaliq
Xultophy 100/3.6
At A Glance
Oral
Daily
HMG-CoA reductase inhibitor
SC injection
Once daily
Basal insulin/GLP-1 receptor agonist combination
Indications
- Coronary heart disease
- Diabetes Mellitus, Non-Insulin-Dependent
- Heart failure
- Hyperlipidemia
- Hypercholesterolemia, Familial
- Hypertriglyceridemia
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Coronary heart disease, Diabetes Mellitus Non-Insulin-Dependent, Heart failure, Hyperlipidemia, Hypertriglyceridemia 10 or 20 mg once daily orally on an empty stomach; dosage range 10-80 mg once daily; patients requiring LDL-C reduction >45% may start at 40 mg once daily.
Hypercholesterolemia, Familial (HeFH, pediatric >= 10 years) 10 mg once daily orally on an empty stomach; dosage range 10-20 mg once daily.
Hypercholesterolemia, Familial (HoFH, pediatric >= 10 years) 10-20 mg once daily orally on an empty stomach; dosage range 10-80 mg once daily.
Diabetes Mellitus, Non-Insulin-Dependent Patients naive to basal insulin or GLP-1 receptor agonist: start 10 units SC once-daily; patients currently on basal insulin or GLP-1 receptor agonist: start 16 units SC once-daily (discontinue prior therapy first); titrate by 2 units once or twice weekly based on fasting plasma glucose; maximum 50 units/day.
Contraindications
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to atorvastatin or any excipients in ATORVALIQ
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Episodes of hypoglycemia
- Hypersensitivity to insulin degludec, liraglutide, or any excipient in Xultophy 100/3.6
Adverse Reactions
Most common (>=2%) Nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngeal pain
Serious Myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose
Postmarketing Pancreatitis, fatigue, fatal and non-fatal hepatic failure, anaphylaxis, tendon rupture, rhabdomyolysis, myositis, dizziness, peripheral neuropathy, cognitive impairment, depression, interstitial lung disease, angioneurotic edema, bullous rashes
Most common (>=5%) Nasopharyngitis, headache, nausea, diarrhea, increased lipase, upper respiratory tract infection, hypoglycemia
Serious Thyroid C-cell tumors, acute pancreatitis, hypoglycemia, acute kidney injury, severe gastrointestinal reactions, hypersensitivity reactions including anaphylaxis, acute gallbladder disease, hypokalemia, pulmonary aspiration
Postmarketing Localized cutaneous amyloidosis, acute and necrotizing pancreatitis, hepatitis, cholecystitis, angioedema, anaphylactic reactions, medullary thyroid carcinoma, acute renal failure, alopecia
Pharmacology
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a cholesterol precursor; it lowers plasma cholesterol and LDL levels by inhibiting hepatic cholesterol synthesis and increasing hepatic LDL receptor expression.
Xultophy 100/3.6 combines insulin degludec, a long-acting basal insulin analog that lowers blood glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production, with liraglutide, a GLP-1 receptor agonist that increases glucose-dependent insulin release, decreases glucagon secretion, and slows gastric emptying.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
No coverage data available for Atorvaliq.
Xultophy 100/3.6
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (7/12) · Qty limit (9/12)
UnitedHealthcare
No coverage data available for Atorvaliq.
Xultophy 100/3.6
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
No coverage data available for Atorvaliq.
Xultophy 100/3.6
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Atorvaliq.
No savings programs available for Xultophy 100/3.6.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AtorvaliqView full Atorvaliq profile
Xultophy 100/3.6View full Xultophy 100/3.6 profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.